CCKBR and medullary thyroid gland carcinoma: Molecular imaging and peptide receptor radionuclide therapy (PRRT) approaches can exploit the overexpression of cholecystokinin subtype 2 receptors (CCK2R) at an incidence of over 90% in MTC (Reubi et al., 1997; Reubi and Waser, 1996).